ImpediMed Limited announced the appointment of Michael Seiden, MD, PhD and Daniel Sharp, CFA as independent Non-executive Directors, effective 1 July 2023. Dr Seiden is a Board-Certified Medical Oncologist who brings a broad background of leadership positions across the cancer care and business ecosystems. His previous experience includes serving as president of US Oncology Network, a McKesson owned company that includes the largest collection of community-based oncology care practices in the United States. He also served as CEO and President of Fox Chase Cancer Center, a National Cancer Institute designated research center as well as a founding member of the National Comprehensive Cancer Network (NCCN®).

Mr. Sharp brings a wealth of capital markets expertise to the board. Until his retirement in 2020, Mr. Sharp was responsible for Equity Capital Market banking transactions and corporate advisory services in the life sciences and healthcare sector at Canaccord Genuity Australia. He currently serves as a Non-executive Director at Alcidion Group and Botanix Pharmaceuticals and is a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation.